Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kevin Kalinsky, Mafalda Oliveira, Tiffany A. Traina, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Sara A. Hurvitz, Filipa Lynce, Erika P. Hamilton, Rita Nanda, Lowell L. Hart, Paul D. Richards, Zulfiqar A. Malik, Hope S. Rugo, Veronique Dieras, Aditya Bardia, Quan Hong, Martin Sebastian Olivo, Loretta Itri, Sibylle Loibl
Institutions: Emory University, Winship Cancer Institute, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Institut Curie, Universitair Ziekenhuis Leuven, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Tennessee Oncology, University of Chicago Medical Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Centre Eugène Marquis, Harvard University, Massachusetts General Hospital, Immunomedics (United States)
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3170772776